Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and po

Trial Details

NCT ID
NCT06814496
Phase
PHASE1 / PHASE2
Sponsor
University of Arizona
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Tarlatamab
  • Concurrent Radiation Therapy
  • Sequential Radiation therapy
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
  • Subjects ≥ 18 years of age at the time of signing the informed consent.
  • Histologically or cytologically confirmed relapsed/refractory:
  • Other tumors of small cell histology

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →